$12.97
+0.15 (+1.17%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PRGO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 15 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, Man Group plc, SUSQUEHANNA INTERNATIONAL GROUP, LLP, GABELLI FUNDS LLC, +10 more) · FINRA short interest 8.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common ColdNCT01744106Nasal Congestion Severity (NCSi) (instantaneous) scoresRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: pseudoephedrine hydrochloride 30 mg tablets, Placebo tablets | Nasal Congestion Associated With the Common Cold | 565 | Apr 2016actual | 2016-04-22 |
| Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed ConditionsNCT00803764Bioequivalence was assessed on the pharmacokinetic variables Cmax, AUC,0-t, and AUC,0-infinityRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Naproxen Tablets, 500 mg | Bioequivalency | 34 | Jul 2004actual | 2012-03-16 |
| Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting ConditionsNCT00804401Bioequivalence was assessed on the pharmacokinetic variables Cmax, AUC,0-t, and AUC,0-infinityRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Naproxen Tablets, 500 mg | Bioequivalency | 34 | Jul 2004actual | 2012-03-16 |
| Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting ConditionsNCT00802828Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinityRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Famotidine Tablets, 40 mg | Bioavailability | 44 | Jun 2004actual | 2012-03-16 |
| Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed ConditionsNCT00803192Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Famotidine Tablets, 40 mg | Bioavailability | 44 | Jun 2004actual | 2012-03-16 |
| Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting ConditionsNCT00804440Bioequivalence was assessed on the pharmacokinetic variables Cmax, AUC,0-t, and AUC,0-infinityRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ibuprofen Tablets, 800 mg | Bioequivalency | 30 | Jan 2004actual | 2012-03-16 |
| Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed ConditionsNCT00803946Bioequivalence was assessed on the pharmacokinetic variables Cmax, AUC,0-t, and AUC,0-infinityRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ibuprofen Tablets, 800 mg | Bioequivalency | 30 | Nov 2003actual | 2012-03-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19